920-P: Sodium–Glucose Cotransporter 2 Inhibitor Use and Risk of Dementia and Parkinson’s disease among Patients with Type 2 Diabetes—A Longitudinal, Nationwide, Population-Based Cohort Study

IF 6.2 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2024-06-21 DOI:10.2337/db24-920-p

HAE KYUNG KIM, GEERT J. BIESSELS, MINHEUI YU, JIHOON BAE, ARIM CHOI, MINYOUNG LEE

{"title":"920-P: Sodium–Glucose Cotransporter 2 Inhibitor Use and Risk of Dementia and Parkinson’s disease among Patients with Type 2 Diabetes—A Longitudinal, Nationwide, Population-Based Cohort Study","authors":"HAE KYUNG KIM, GEERT J. BIESSELS, MINHEUI YU, JIHOON BAE, ARIM CHOI, MINYOUNG LEE","doi":"10.2337/db24-920-p","DOIUrl":null,"url":null,"abstract":"The efficacy of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in neurologic disorders is not well-established. This study aimed to investigate the association of SGLT2i use with risks of incident dementia and Parkinson’s disease (PD) in patient with type 2 diabetes. Subjects aged ≥ 40 years, diagnosed with type 2 diabetes, and who started antidiabetic drugs from 1 September 2014 and 31 December 2019 were evaluated, using the National Health Insurance Service Database. Propensity score matching (1:1; SGLT2i to other oral antidiabetic drugs [OAD]) produced a cohort of 358,862. Primary outcomes were a composite of dementia from any cause (Alzheimer’s disease [AD], vascular dementia [VaD], and other dementia) and PD. From the 358,862 participants analyzed (mean age, 57.8 years; 57.9% male), 6,837 incident dementia or PD events occurred. Overall, use of SGLT2i was associated with a 22% lower risk for the composite of dementia from any cause and PD than use of other OADs (adjusted HR [aHR], 0.78 [95% CI 0.73─0.83]) with a 6-month lag period. Regarding the individual endpoints, SGLT2i use was associated with reduced risks for AD (aHR, 0.81 [95% CI 0.76─0.87]), VaD (aHR, 0.69 [95% CI 0.60─0.78]), and PD (aHR, 0.80 [95% CI 0.69─0.91]). In this nationwide population-based cohort study, SGLT2i use significantly reduced the risks for dementia and PD in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters. Disclosure H. Kim: None. G.J. Biessels: None. M. Yu: None. J. Bae: None. A. Choi: None. M. Lee: Other Relationship; JW Pharmaceutical Corporation, Boryung Corporation, Eli Lilly and Company, Merck Sharp & Dohme Corp., HK inno.N, Servier Korea, Handok Inc., Daewoong Pharmaceutical, KUKJE PHARM CO., LTD, GC Biopharma Corporation. Funding Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HR22C141104)2); 'SENTINEL (Severance Endocrinology daTa scIeNcE pLatform)’ program funded by the 2020 Research fund of Department of Internal Medicine, Severance Hospital; Sung-Kil Lim Research Award (4-2018-1215; DUCD000002); Yonsei University College of Medicine (6-2020-0155)","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":null,"pages":null},"PeriodicalIF":6.2000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-920-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

The efficacy of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in neurologic disorders is not well-established. This study aimed to investigate the association of SGLT2i use with risks of incident dementia and Parkinson’s disease (PD) in patient with type 2 diabetes. Subjects aged ≥ 40 years, diagnosed with type 2 diabetes, and who started antidiabetic drugs from 1 September 2014 and 31 December 2019 were evaluated, using the National Health Insurance Service Database. Propensity score matching (1:1; SGLT2i to other oral antidiabetic drugs [OAD]) produced a cohort of 358,862. Primary outcomes were a composite of dementia from any cause (Alzheimer’s disease [AD], vascular dementia [VaD], and other dementia) and PD. From the 358,862 participants analyzed (mean age, 57.8 years; 57.9% male), 6,837 incident dementia or PD events occurred. Overall, use of SGLT2i was associated with a 22% lower risk for the composite of dementia from any cause and PD than use of other OADs (adjusted HR [aHR], 0.78 [95% CI 0.73─0.83]) with a 6-month lag period. Regarding the individual endpoints, SGLT2i use was associated with reduced risks for AD (aHR, 0.81 [95% CI 0.76─0.87]), VaD (aHR, 0.69 [95% CI 0.60─0.78]), and PD (aHR, 0.80 [95% CI 0.69─0.91]). In this nationwide population-based cohort study, SGLT2i use significantly reduced the risks for dementia and PD in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters. Disclosure H. Kim: None. G.J. Biessels: None. M. Yu: None. J. Bae: None. A. Choi: None. M. Lee: Other Relationship; JW Pharmaceutical Corporation, Boryung Corporation, Eli Lilly and Company, Merck Sharp & Dohme Corp., HK inno.N, Servier Korea, Handok Inc., Daewoong Pharmaceutical, KUKJE PHARM CO., LTD, GC Biopharma Corporation. Funding Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HR22C141104)2); 'SENTINEL (Severance Endocrinology daTa scIeNcE pLatform)’ program funded by the 2020 Research fund of Department of Internal Medicine, Severance Hospital; Sung-Kil Lim Research Award (4-2018-1215; DUCD000002); Yonsei University College of Medicine (6-2020-0155)

查看原文本刊更多论文

920-P：钠-葡萄糖共转运体 2 抑制剂的使用与 2 型糖尿病患者罹患痴呆症和帕金森病的风险--一项纵向、全国性、基于人群的队列研究

钠-葡萄糖共转运体 2 抑制剂（SGLT2i）对神经系统疾病的疗效尚未得到充分证实。本研究旨在探讨使用 SGLT2i 与 2 型糖尿病患者痴呆症和帕金森病（PD）发病风险的关系。研究利用国家健康保险服务数据库对年龄≥40岁、确诊为2型糖尿病且在2014年9月1日至2019年12月31日期间开始服用抗糖尿病药物的受试者进行了评估。倾向得分匹配（1:1；SGLT2i 与其他口服抗糖尿病药物 [OAD]）产生了一个 358,862 人的队列。主要结果是任何原因引起的痴呆（阿尔茨海默病 [AD]、血管性痴呆 [VaD] 和其他痴呆）和帕金森病的复合结果。在分析的 358862 名参与者（平均年龄 57.8 岁；57.9% 为男性）中，发生了 6837 例痴呆或帕金森病事件。总体而言，使用 SGLT2i 与任何原因引起的痴呆和帕金森氏症的复合风险相关性比使用其他 OADs 低 22%（调整 HR [aHR]，0.78 [95% CI 0.73-0.83]），滞后期为 6 个月。就单个终点而言，使用 SGLT2i 可降低 AD（aHR，0.81 [95% CI 0.76─0.87]）、VaD（aHR，0.69 [95% CI 0.60─0.78]）和 PD（aHR，0.80 [95% CI 0.69─0.91]）的风险。在这项全国范围的人群队列研究中，使用SGLT2i能显著降低2型糖尿病患者罹患痴呆症和帕金森氏症的风险，不受合并症和生物临床参数等各种因素的影响。披露 H. Kim：无。G.J. Biessels：无。M. Yu：无。J. Bae：无。A. Choi：无。M. Lee：其他关系；JW Pharmaceutical Corporation、Boryung Corporation、Eli Lilly and Company、Merck Sharp & Dohme Corp.、HK inno.N、Servier Korea、Handok Inc.、Daewoong Pharmaceutical、KUKJE PHARM CO.，LTD、GC Biopharma Corporation。资金来源韩国保健产业振兴院（KHIDI）资助的韩国保健技术研发项目（HR22C141104)2）；Severance医院内科2020研究基金资助的 "SENTINEL（Severance Endocrinology daTa scIeNcE pLatform）"项目；Sung-Kil Lim研究奖（4-2018-1215；DUCD000002）；延世大学医学院（6-2020-0155）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.